Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study

被引:0
|
作者
Fonteyne, Valerie [1 ]
Danckaert, Willeke [1 ]
Ost, Piet [2 ]
Berghen, Charlien [3 ]
Vandecasteele, Katrien [1 ]
Vanneste, Ben [1 ]
Rans, Kato [3 ]
Liefhooghe, Nick [4 ]
Wallaert, Steven [5 ]
Paelinck, Leen [1 ]
机构
[1] Ghent Univ Hosp, Dept Radiotherapy & Oncol, C Heymanslaan 10, B-9000 Ghent, Belgium
[2] Univ Ghent, Dept Human Struct & Repair, Ghent, Belgium
[3] Univ Hosp Leuven, Dept Radiotherapy & Oncol, Louvain, Belgium
[4] AZ Groeninge, Dept Radiotherapy & Oncol, Kortrijk, Belgium
[5] Univ Ghent, Dept Med & Hlth Sci, Ghent, Belgium
关键词
radiotherapy; toxicity; radiation dosimetry; prostate cancer; cancer treatment;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The aim is to evaluate the incidental dose to the lymphatic regions in prostate-only radiotherapy (PORT) and to compare hematological outcome between PORT and whole pelvic radiotherapy (WPRT) in node-positive prostate cancer (pN1 PCa), in the era of modern radiotherapy techniques. Methods: We performed a prospective phase 3 trial in which a total of 64 pN1 PCa patients were randomized between PORT (ARM A) and WPRT (ARM B) delivered with volumetric-modulated arc therapy (VMAT). The lymph node (LN) regions were delineated separately and differences between groups were calculated using Welch t-tests. Hematological toxicity was scored according to common terminology criteria for adverse events (CTCAE) version 4.03. To evaluate differences in the evolution of red blood cell (RBC), white blood cell (WBC), and platelet count over time between PORT and WPRT, 3 linear mixed models with a random intercept for the patient was fit with model terms randomization group, study time point, and the interaction between both categorical predictors. Results: Except for dose to the obturator region, the incidental dose to the surrounding LN areas was low in ARM A. None of the patients developed severe hematological toxicity. The change in RBC from time point pre-external beam radiotherapy (EBRT) to month 3 and for WBC from time point pre-EBRT to months 3 and 12 was significantly different with ARM B showing a larger decrease. Conclusion: The incidental dose to the lymphatic areas becomes neglectable when PORT is delivered with VMAT. Hematological toxicity is very low after WPRT with VMAT and when bone marrow constraints are used for planning, although WPRT causes a decrease in RBC and WBC count over time.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Dosimetric and Hematologic Implications of Prostate-Only Versus Whole Pelvic Radiotherapy: Results of the Multicentric Phase 3 PROPER Study
    Fonteyne, Valerie
    Danckaert, Willeke
    Ost, Piet
    Berghen, Charlien
    Vandecasteele, Katrien
    Vanneste, Ben
    Rans, Kato
    Liefhooghe, Nick
    Wallaert, Steven
    Paelinck, Leen
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [2] Efficacy and Toxicity of Whole Pelvic Radiotherapy Versus Prostate-Only Radiotherapy in Localized Prostate Cancer: A Systematic Review and Meta-Analysis
    Wang, Shilin
    Tang, Wen
    Luo, Huanli
    Jin, Fu
    Wang, Ying
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [3] QUALITY OF LIFE AFTER WHOLE PELVIC VERSUS PROSTATE-ONLY EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER: A MATCHED-PAIR COMPARISON
    Pinkawa, Michael
    Piroth, Marc D.
    Holy, Richard
    Fischedick, Karin
    Klotz, Jens
    Szekely-Orban, Dalma
    Eble, Michael J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (01): : 23 - 28
  • [4] Quantitative Evaluation of a Fully Automated Planning Solution for Prostate-Only and Whole-Pelvic Radiotherapy
    Prunaretty, Jessica
    Ungun, Baris
    Vauclin, Remi
    Costea, Madalina
    Bus, Norbert
    Paragios, Nikos
    Fenoglietto, Pascal
    CANCERS, 2024, 16 (22)
  • [5] Evaluating the Impact of Prostate Only Versus Pelvic Radiotherapy for Pathological Node-positive Prostate Cancer: First Results from the Multicenter Phase 3 PROPER Trial
    Fonteyne, Valerie
    Van Praet, Charles
    Ost, Piet
    Van Bruwaene, Siska
    Liefhooghe, Nick
    Berghen, Charlien
    De Meerleer, Gert
    Vanneste, Ben
    Verbaeys, Caroline
    Verbeke, Sofie
    Lumen, Nicolaas
    EUROPEAN UROLOGY FOCUS, 2023, 9 (02): : 317 - 324
  • [6] WHOLE PELVIC RADIOTHERAPY VERSUS PROSTATE ONLY RADIOTHERAPY IN THE MANAGEMENT OF LOCALLY ADVANCED OR AGGRESSIVE PROSTATE ADENOCARCINOMA
    Aizer, Ayal A.
    Yu, James B.
    McKeon, Anne M.
    Decker, Roy H.
    Colberg, John W.
    Peschel, Richard E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05): : 1344 - 1349
  • [7] Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation therapy oncology group 9413
    Roach, M
    DeSilvio, M
    Lawton, C
    Uhl, V
    Machtay, M
    Seider, MJ
    Rotman, M
    Jones, C
    Asbell, SO
    Valicenti, RK
    Han, S
    Thomas, CR
    Shipley, WS
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (10) : 1904 - 1911
  • [8] Patterns of Failure After Prostate-Only Radiotherapy in High-Risk Prostate Cancer: Implications for Refining Pelvic Nodal Contouring Guidelines
    Singh, M.
    Maitre, P.
    Mody, R.
    Murthy, V.
    CLINICAL ONCOLOGY, 2024, 36 (07) : 445 - 451
  • [9] Whole pelvis versus prostate-only radiotherapy with or without short course androgen deprivation therapy and mortality risk
    Braunstein, Lior Z.
    Chen, Ming-Hui
    Dosoretz, Daniel E.
    Salenius, Sharon
    Katin, Michael
    Nanda, Akash
    D'Amico, Anthony V.
    CANCER RESEARCH, 2015, 75
  • [10] CLINICAL TOXICITIES AND DOSIMETRIC PARAMETERS AFTER WHOLE-PELVIS VERSUS PROSTATE-ONLY INTENSITY-MODULATED RADIATION THERAPY FOR PROSTATE CANCER
    Deville, Curtiland
    Both, Stefan
    Hwang, Wei-Ting
    Tochner, Zelig
    Vapiwala, Neha
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : 763 - 772